MEC Plus Full List View

By pinki@katapult.biz / February 16, 2025

Selecting the Best Frontline Therapy for Transplant Eligible Myeloma Patients

Selecting the Best Frontline Therapy for Transplant Eligible Myeloma Patients

Saad Usmani, MD, MBA, FACP

Novel Advances in Myelofibrosis: Diagnosis-Risk Stratification-Therapy

Novel Advances in Myelofibrosis: Diagnosis-Risk Stratification-Therapy

Gabriela S. Hobbs, MD

Acquired Inhibitors in Cancer: State-of-the Art Management

Acquired Inhibitors in Cancer: State-of-the Art Management

Cindy Leissinger, MD

Novel Therapeutic Strategies for MDS Based on Molecular Profile

Rami Komrokji, MD

CAR-T Cell Therapy in Lymphomas: 7-Years Later

CAR-T Cell Therapy in Lymphomas: 7-Years Later

Mohamed A. Kharfan-Dabaja, MD, MBA, FACP

De Novo Acute Myeloid Leukemia

De Novo Acute Myeloid Leukemia

Hugo F. Fernandez, MD

Targeted Therapy in Hema Malignancies (CD20, CD30, CD33, BCR/ABL, FLT3, IDH1/2)

Targeted Therapy in Hema Malignancies (CD20, CD30, CD33, BCR/ABL, FLT3, IDH1/2)

Brian Primeaux, PharmD, BCOP

CLL: Therapeutic Advances in 2024

CLL: Therapeutic Advances in 2024

Javier Pinilla-Ibarz, MD, PhD

Navigating Mantle Cell Lymphoma in the Era of Targeted Therapy

Navigating Mantle Cell Lymphoma in the Era of Targeted Therapy

Nakhle Saba, MD

What Is New for DLBCL and & Hodgkin’s Disease?

What Is New for DLBCL and & Hodgkin’s Disease?

Eduardo Sotomayor, MD

Novel Advances in T-Cell NHL Therapies

Novel Advances in T-Cell NHL Therapies

Luis E. Fayad, MD

Small Cell Lung Cancer: Targeting This Difficult Target

Small Cell Lung Cancer: Targeting This Difficult Target

Anne Chiang, MD, PhD

Non Driver NSCLC: The Immunotherapy Strategy

Non Driver NSCLC: The Immunotherapy Strategy

Luis E. Raez, MD, FACP, FCCP, FASCO

Other Driver Mutations: ROS-1, BRAF, MET and RET

Other Driver Mutations: ROS-1, BRAF, MET and RET

Erminia Massarelli, MD, PhD, MS

K-RAS Therapies in NSCLC

K-RAS Therapies in NSCLC

Julia Rotow, MD

ALK: First Line and Mechanism Of Resistance

ALK: First Line and Mechanism Of Resistance

Sai-Hong Ignatius Ou, MD, PhD

EGFR Exon 20 Insertions: Novel Agents

EGFR Exon 20 Insertions: Novel Agents

Millie Das, MD

What Is Next After Osimertinib Progression?

What Is Next After Osimertinib Progression?

Mark A. Socinski, MD

Lung Cancer With EGFR Exon 19 and L858R Mutations: The Optimal Front Line Therapy

Lung Cancer With EGFR Exon 19 and L858R Mutations: The Optimal Front Line Therapy

Jonathan Riess, MD, MS

Adjuvant Therapies in NSCLC

Adjuvant Therapies in NSCLC

Karen Kelly, MD

Optimal Surgical Approach in Early Stages NSCLC

Optimal Surgical Approach in Early Stages NSCLC

David H. Harpole, Jr., MD

Screening in Lung Cancer: Challenges and Obstacles

Screening in Lung Cancer: Challenges and Obstacles

Claudia Henschke, MD, PhD

Challenges in Lung Cancer Pathology: Biomarkers

Challenges in Lung Cancer Pathology: Biomarkers

Ignacio Wistuba, MD

ctDNA in Lung Cancer: Current State and Future Perspectives

ctDNA in Lung Cancer: Current State and Future Perspectives

Christian Rolfo, MD, PhD, MBA, Dr.hc.

Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (NO)

Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (NO)

Cesar A. Santa-Maria, MD, MSCI

Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (YES)

Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (YES)

Lajos Puzstai, MD, DPhil, FASCO

Immunotherapy for Breast Cancer: Efficacy and Toxicity Considerations

Immunotherapy for Breast Cancer: Efficacy and Toxicity Considerations

Heather McArthur, MD, MPH

Applying New Endocrine and Targeted Agents to the Treatment of Hormone Receptor Positive, HER2 Negative Breast Cancer

Applying New Endocrine and Targeted Agents to the Treatment of Hormone Receptor Positive, HER2 Negative Breast Cancer

Mariana Chavez-McGregor, MD, MSc, FASCO

New and Evolving Directions in the Treatment of HER2 Positive Breast Cancer

New and Evolving Directions in the Treatment of HER2 Positive Breast Cancer

Mark Pegram, MD

Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer

Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer

Hope S. Rugo, MD, FASCO